Bayer's Leadership Prepares For First Innovative Drug Launch In China Ahead Of U.S.

BEIJING - After obtaining regulatory approval for an innovative new anticoagulant in Beijing while a simultaneously filed application is still being reviewed by the U.S. FDA in Washington, DC, the leadership of Bayer Schering Pharma AG is now crafting a plan for the release of the drug in China ahead of the United States

More from Archive

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?